HK1102760A1 - Anti-psgl-1 antibodies - Google Patents

Anti-psgl-1 antibodies

Info

Publication number
HK1102760A1
HK1102760A1 HK07110370.2A HK07110370A HK1102760A1 HK 1102760 A1 HK1102760 A1 HK 1102760A1 HK 07110370 A HK07110370 A HK 07110370A HK 1102760 A1 HK1102760 A1 HK 1102760A1
Authority
HK
Hong Kong
Prior art keywords
psgl
antibodies
Prior art date
Application number
HK07110370.2A
Other languages
English (en)
Inventor
Rong-Hwa Lin
Chung Nan Chang
Pei-Jiun Chen
Chiu-Chen Huang
Original Assignee
ABGENOMICS COöPERATIEF U A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1102760(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ABGENOMICS COöPERATIEF U A filed Critical ABGENOMICS COöPERATIEF U A
Publication of HK1102760A1 publication Critical patent/HK1102760A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK07110370.2A 2004-05-10 2007-09-24 Anti-psgl-1 antibodies HK1102760A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
PCT/US2005/016357 WO2005110475A2 (en) 2004-05-10 2005-05-10 Antibodies

Publications (1)

Publication Number Publication Date
HK1102760A1 true HK1102760A1 (en) 2007-12-07

Family

ID=35394680

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07110370.2A HK1102760A1 (en) 2004-05-10 2007-09-24 Anti-psgl-1 antibodies

Country Status (28)

Country Link
US (8) US7604800B2 (ja)
EP (3) EP1765396B1 (ja)
JP (4) JP5623690B2 (ja)
KR (1) KR101256400B1 (ja)
CN (2) CN103980361B (ja)
AR (1) AR048781A1 (ja)
AU (1) AU2005244072C1 (ja)
BR (1) BRPI0510567B8 (ja)
CA (3) CA2566305C (ja)
DK (1) DK1765396T3 (ja)
EC (1) ECSP067056A (ja)
EG (1) EG26781A (ja)
ES (3) ES2598034T3 (ja)
HK (1) HK1102760A1 (ja)
IL (3) IL178838A (ja)
MX (1) MXPA06012986A (ja)
MY (1) MY148646A (ja)
NO (1) NO341844B1 (ja)
NZ (3) NZ590690A (ja)
PH (1) PH12015500247A1 (ja)
PL (1) PL1765396T3 (ja)
PT (1) PT1765396E (ja)
RU (1) RU2482131C2 (ja)
SG (2) SG10201606541UA (ja)
TW (2) TWI402274B (ja)
UA (1) UA100356C2 (ja)
UY (1) UY28886A1 (ja)
WO (1) WO2005110475A2 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
EP1751300B1 (en) 2004-05-11 2017-11-08 AbGenomics Coöperatief U.A. T-cell death-inducing epitopes
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
US8722856B2 (en) * 2008-10-28 2014-05-13 National University Corporation Hokkaido University Anti-MUC1 antibody
TWI496295B (zh) * 2008-10-31 2015-08-11 Semiconductor Energy Lab 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
WO2012000094A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
AU2012325013A1 (en) 2011-10-17 2014-03-27 Westfaelische Wilhelms-Universitaet Muenster Methods of risk assessment of PML and related apparatus
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
US10988528B2 (en) * 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
CN108713026B (zh) * 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND USES THEREOF
MY200609A (en) 2017-03-14 2024-01-05 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
JP2022535550A (ja) * 2019-06-04 2022-08-09 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
US20230144203A1 (en) * 2020-01-22 2023-05-11 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
AU2022394559A1 (en) * 2021-11-17 2024-05-09 Altrubio Inc. Methods of using anti-psgl-1 antibodies in combination with jak inhibitors to treat t-cell mediated inflammatory diseases or cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ES2131107T3 (es) * 1992-03-17 1999-07-16 Novartis Ag Anticuerpos obtenidos mediante ingenieria genetica.
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
NZ261991A (en) 1993-01-25 1998-04-27 Dana Farber Cancer Inst Inc Chimeric l and p selectin made by exchange of domains, uses thereof
PL311666A1 (en) * 1993-05-04 1996-03-04 Cytel Corp P-selection antibodies and their application
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
AU723262B2 (en) 1995-08-03 2000-08-24 Board Of Regents Of The University Of Oklahoma, The Peptide and O-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
MXPA01004310A (es) * 1998-10-30 2003-06-06 Cbr Lab Inc Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
AU2000274809A1 (en) * 2000-09-12 2002-03-26 Genetics Institute Llc Inhibition of stenosis or restenosis by p-selectin antagonists
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
IL156689A0 (en) 2000-12-29 2004-01-04 Savient Pharmaceuticals Inc Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
EP1751300B1 (en) * 2004-05-11 2017-11-08 AbGenomics Coöperatief U.A. T-cell death-inducing epitopes
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso

Also Published As

Publication number Publication date
TWI448474B (zh) 2014-08-11
CA2812040C (en) 2016-05-03
ES2598034T3 (es) 2017-01-24
JP5623690B2 (ja) 2014-11-12
US20130102762A1 (en) 2013-04-25
TWI402274B (zh) 2013-07-21
JP2014094010A (ja) 2014-05-22
MXPA06012986A (es) 2007-02-12
TW200536860A (en) 2005-11-16
US10030075B2 (en) 2018-07-24
EG26781A (en) 2014-09-07
US8361472B2 (en) 2013-01-29
SG187443A1 (en) 2013-02-28
US20090191204A1 (en) 2009-07-30
CN103980361A (zh) 2014-08-13
EP2377889A2 (en) 2011-10-19
BRPI0510567B8 (pt) 2021-05-25
US20170190782A1 (en) 2017-07-06
US8287871B2 (en) 2012-10-16
US20110172397A1 (en) 2011-07-14
EP2377890A3 (en) 2011-12-28
PT1765396E (pt) 2014-02-25
NZ578647A (en) 2012-04-27
CA2907141A1 (en) 2005-11-24
ES2602633T3 (es) 2017-02-21
JP2011200247A (ja) 2011-10-13
EP2377889B1 (en) 2016-07-13
US20150183870A1 (en) 2015-07-02
NZ590690A (en) 2012-10-26
PL1765396T3 (pl) 2014-07-31
KR101256400B1 (ko) 2013-04-26
US20090198044A1 (en) 2009-08-06
CN103980361B (zh) 2017-06-23
AU2005244072C1 (en) 2012-09-20
EP1765396A4 (en) 2008-07-02
PH12015500247A1 (en) 2015-12-14
IL228033A0 (en) 2013-09-30
RU2006143686A (ru) 2008-06-20
CN1984680B (zh) 2014-11-05
DK1765396T3 (en) 2014-02-24
EP1765396B1 (en) 2013-11-20
BRPI0510567B1 (pt) 2018-11-13
JP2014223084A (ja) 2014-12-04
AU2005244072A1 (en) 2005-11-24
WO2005110475A2 (en) 2005-11-24
TW201313740A (zh) 2013-04-01
UA100356C2 (ru) 2012-12-25
NZ551626A (en) 2010-03-26
IL178838A0 (en) 2007-03-08
BRPI0510567A (pt) 2007-11-20
EP1765396A2 (en) 2007-03-28
WO2005110475A3 (en) 2006-02-23
EP2377890B1 (en) 2016-08-10
IL228032A0 (en) 2013-09-30
RU2482131C2 (ru) 2013-05-20
IL178838A (en) 2017-08-31
SG10201606541UA (en) 2016-09-29
CA2566305A1 (en) 2005-11-24
EP2377889A3 (en) 2012-03-28
US9631019B2 (en) 2017-04-25
CA2907141C (en) 2016-05-31
NO341844B1 (no) 2018-02-05
AU2005244072B2 (en) 2012-05-31
CA2566305C (en) 2014-10-14
CN1984680A (zh) 2007-06-20
AR048781A1 (es) 2006-05-24
EP2377890A2 (en) 2011-10-19
US8663641B2 (en) 2014-03-04
CA2812040A1 (en) 2005-11-24
JP2007536933A (ja) 2007-12-20
MY148646A (en) 2013-05-15
UY28886A1 (es) 2005-12-30
ES2448468T3 (es) 2014-03-14
US20050266003A1 (en) 2005-12-01
US20130101587A1 (en) 2013-04-25
KR20070020048A (ko) 2007-02-16
US7604800B2 (en) 2009-10-20
NO20065542L (no) 2007-01-31
ECSP067056A (es) 2007-01-26
US8828397B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
HK1102760A1 (en) Anti-psgl-1 antibodies
IL181575A0 (en) Anti-ox40l antibodies
TWI307630B (en) Immunoglobulins
TWI365746B (en) Immunoglobulins
IL179672A0 (en) Anti-cd3 antibodies
HRP20130440T1 (en) Anti-p-selectin antibodies
HRP20150176T1 (en) Anti-myostatin antibodies
IL189579A0 (en) Anti-myostatin antibodies
GB0517487D0 (en) Antibodies
GB0420466D0 (en) Anti-glucan antibodies
HK1105993A1 (en) Anti-a33 antibody
EP1718749A4 (en) ANTI-AF-20 HUMANIZED MONOCLONAL ANTIBODY
ZA200701952B (en) Anti-OX40L antibodies
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
ZA200610612B (en) Immunoglobulins
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
EP1712564A4 (en) MONOCLONAL ANTIBODY ANTI-NC1
GB0505489D0 (en) Antibodies
GB0418415D0 (en) Antibody
GB0407197D0 (en) Immunoglobulins
GB0415644D0 (en) Monoclonal antibody
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0420771D0 (en) Antibody
GB0402641D0 (en) Antibodies